During UNCOVER-2 and UNCOVER-3 trials (50) where ixekizumab (an IL-17 inhibitor) was versus etanercept (a TNF-α inhibitor) or placebo with psoriasis, two MACEs events were reported in the ixekizumab group. Here, IL17A is linked to psoriasis.